New immunologically non-specific immunosuppressive agents dictate changes in standard protocols for renal transplant management

Nephrology Dialysis Transplantation

Volumn 12, Issue SUPPL. 1, 1997, Pages 51-54

  Helderman, J H ^a,b  

^a Vanderbilt University Transplant Center   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

CELL CYCLE; CONFERENCE PAPER; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LYMPHOCYTE; PARENCHYMA; PRIORITY JOURNAL;

CLINICAL PROTOCOLS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 0031044181     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.1.51     Document Type: Conference Paper

References (9)

1. Helderman JH, Van Buren DH, Amend WJC, Pirsch JD. Chronic immunosuppression of the renal transplant patient. J Am Soc Nephrol 1994; 4: S2-S9
2. Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161
3. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991; 33: 175
4. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection [abstract]. Lancet 1995; 345(8961): 1321-1325
5. Sollinger HW. Mycophenolate for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225
6. Kimball PM, Kerman RH, Kahan BD. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 1991; 51(2): 486-490
7. Morris RE. Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action. Ann NY Acad Sci 1993; 685: 58-67.
8. Niese D (The International Sandimmune Neoral Study Group). A double-blind randomized study of Sandimmune Neoral® versus Sandimmune in new renal transplant recipients: results after 12 months. Transplant Proc 1995; 27(2); 1849-1856
9. Almond PS et al. Transplantation 1992; 53: 316